LivaNova PLC
NASDAQ:LIVN
LivaNova PLC
NASDAQ:LIVN
Price:
54.5 USD
-2.57%
Market Closed
Updated:
Apr 26, 2024
LivaNova PLC
Revenue
|
LivaNova PLC
Revenue Peer Comparison
Comparables:
SN
LMDX
EKF
AGL
CREO
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
LivaNova PLC
NASDAQ:LIVN
|
Revenue
$1.2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Smith & Nephew PLC
LSE:SN
|
Revenue
$5.5B
|
CAGR 3-Years
7%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
LumiraDx Ltd
NASDAQ:LMDX
|
Revenue
$254.5m
|
CAGR 3-Years
123%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
EKF Diagnostics Holdings PLC
LSE:EKF
|
Revenue
£52.6m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
|
Angle PLC
LSE:AGL
|
Revenue
£1.8m
|
CAGR 3-Years
31%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Creo Medical Group PLC
LSE:CREO
|
Revenue
£27.2m
|
CAGR 3-Years
1 163%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
LivaNova PLC
Revenue Breakdown
Breakdown by Geography
LivaNova PLC
LivaNova PLC
|
Total Revenue:
1.2B
USD
|
|
United States:
635m
USD
|
|
Rest Of World:
303.7m
USD
|
|
Europe:
214.8m
USD
|
|
United Kingdom:
41.5m
USD
|
Breakdown by Segments
LivaNova PLC
LivaNova PLC
|
Total Revenue:
1.2B
USD
|
|
Cardiopulmonary Segment:
589m
USD
|
|
Neuromodulation Segment:
519.7m
USD
|
|
Advanced Circulatory Support Segment:
40.3m
USD
|
See Also
What is LivaNova PLC's Revenue?
Revenue
1.2B
USD
1.2B
USD
Based on the financial report for Dec 31, 2023, LivaNova PLC's Revenue amounts to 1.2B USD.
What is LivaNova PLC's Revenue growth rate?
Revenue CAGR 5Y
1%
1%
Over the last year, the Revenue growth was 13%. The average annual Revenue growth rates for LivaNova PLC have been 7% over the past three years , 1% over the past five years .
You don't have any saved screeners yet
